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A B S T R A C T
N-terminal peptides derived from the anti-inﬂammatory peptide, annexin-1, inhibit
neutrophil function but can also induce pro-inﬂammatory effects. Although equine
annexin-1 has been sequenced, its cellular expression and properties have not been
reported. This study has examined whether annexin-1 is present in equine leucocytes and
how the N-terminal peptide, Ac2-26, affects equine neutrophil superoxide production.
Annexin-1expression inequineneutrophils andmononuclear cells and theabilityofAc2-
26 to activate neutrophil p42/44 MAPK were determined by immunoblotting. Equine
neutrophil superoxide production was measured by the reduction of cytochrome (cyt) C
following stimulation with Ac2-26 and the formyl peptide receptor (FPR) agonists, FMLP,
WKYMVm and WKYMVM. Responses were examined in the presence of the pan-FPR
antagonist, BOC-2, and the role of p42/44MAPK in agonist-induced effects was determined
using PD98059. The effect of Ac2-26 on superoxide production in response to serum-treated
zymosan (STZ) was also investigated, and the roles of FPR and p42/44 MAPK ascertained.
Annexin-1 was detected in both equine neutrophils and mononuclear cells using a
polyclonal rabbit anti-human annexin-1 antibody. Ac2-26 (5 105M) induced super-
oxide production in cytochalasin B-primed (48 8 versus 21 9 (unstimulated cells) nmol
cyt C/106 neutrophils) and un-primed cells (37 10 versus 11 5 nmol cyt C/106
neutrophils). FMLP and WKYMVm, but not WKYMVM, also caused superoxide production
in primed neutrophils, suggesting the response was mediated by FPR receptor binding. This
was supported by the marked inhibitory effect of BOC-2 on the responses to Ac2-26 and FMLP
although, interestingly, the effects of WKYMVm were not signiﬁcantly reduced (50 5
(WKYMVm) versus 45 5 (WKYMVm + BOC-2) nmol reduced cyt C/106 neutrophils).
Inhibition of p42/44 MAPK activation with PD98059 signiﬁcantly attenuated superoxide
production in response to Ac2-26, FMLP and WKYMVm and Western blotting showed that
Ac2-26 induced p42/44 MAPK activation. At a concentration which did not cause superoxide
production, Ac2-26 (105M) signiﬁcantly reduced the response to STZ (84 17% inhibition).
This inhibitory effect was attenuated by both BOC-2 and PD98059.
These results suggest that if activation of equine leucocytes in vivo leads to the release
and subsequent cleavage of annexin-1, the N-terminal peptides formed could bind to
neutrophil FPR and decrease free radical production in response to particulate stimuli. This
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could help to reduce local tissue damage but, as Ac2-26 can also stimulate superoxide
production at higher concentrations in an FPR-dependent manner, the amount of free
radical production may depend on the concentration of peptide present.
 2009 Elsevier B.V. All rights reserved.
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Annexin-1 is a 37 kD, glucocorticoid-regulated, endo-
genous anti-inﬂammatory peptide that is present in large
amounts in neutrophils as well as in other blood cells
(Morand et al., 1995). Although the effects of annexin-1 on
neutrophil function are largely inhibitory, cleavage at the
N-terminal domain results in the production of peptides
that have anti-inﬂammatory properties but which can
additionally induce pro-inﬂammatory effects (Movitz and
Dahlgren, 2000; Perretti and Gavins, 2003).
Annexin-1and theN-terminalpeptides, Ac2-26andAc9-
25, have been shown to bind to members of a family of G-
protein coupled receptors known as formyl peptide recep-
tors (FPR; Perretti et al., 2001; Ernst et al., 2004; Karlsson
et al., 2005), leading to activation of the intracellular kinase
p42/44 MAPK (ERK; Walther et al., 2000; Hayhoe et al.,
2006). Human and rabbit neutrophils express FPR and FPR2,
which is also known as FPR like-1 (FPRL-1) or ALXR (lipoxin
A4 receptor), to which the formyl peptide, f-Met-Leu-Phe
(FMLP), binds with high and low afﬁnity, respectively.
However, there is inter-species variability in neutrophil FPR
populationsandintheir responsiveness toFMLP(Braziletal.,
1998;Perretti andGavins,2003).AsingleFPRpopulationhas
been identiﬁed on horse neutrophils to which FMLP binds
with a similar Kd to that of the high afﬁnity site on human
cells although, interestingly, equine neutrophils only
respond functionally to low (nanomolar) concentrations
of FMLP once primed (Brazil et al., 1998).
Despite the sequence of equine annexin-1 having been
reported some time ago (Bryant et al., 2002), there are no
published studies on the expression of the peptide in
equine leucocyte sub-populations, nor showing how
annexin-1 or its N-terminal peptides affect equine
neutrophil activation. In this study we investigated
expression of annexin-1 in equine leucocytes and exam-
ined the effects of the N-terminal peptide, Ac2-26, and
other FPR agonists on superoxide production by equine
neutrophils. The effect of Ac2-26 on superoxide production
in response to another stimulus, opsonised zymosan, has
also been examined. The FPR antagonist BOC-2was used to
establish if the effects of Ac2-26 were FPR mediated. Ac2-
26 activates p42/44 MAPK following receptor binding, and
this intracellular kinase is known to be involved in FMLP-
induced superoxide production (Dewas et al., 2000; Shin
et al., 2005; Hayhoe et al., 2006). Therefore, the effects of
inhibiting p42/44 MAPK activation on equine neutrophil
superoxide production were also investigated.
2. Materials and methods
2.1. Reagents
A rabbit anti-human polyclonal annexin-1 antibody
was purchased from Zymed (Cambridge Biosciences,Cambridge, UK). Antibodies recognising total and phos-
phorylated p42/44 MAPK and isotype matched horse-
radish peroxidase (HRP-conjugated) secondary antibodies
were purchased from New England Biolabs (Hitchin, UK).
The MEK-1 inhibitor, PD98059, which was used to inhibit
activation of p42/44 MAPK, was purchased from Calbio-
chem (Merck Chemicals Ltd., Nottingham, UK). The
annexin-1 N-terminal peptide, Ac2-26 (Ac-Ala-Met-Val-
Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp-Phe-Ile-Glu-Asn-Glu-
Glu-Gln-Glu-Tyr-Val-Gln-Thr-Val-Lys) and the synthetic
peptides WKYMVm (Trp-Lys-Tyr-Met-Val-d-Met), an ago-
nist at FPR and FPRL-1, and WKYMVM (Trp-Lys-Tyr-Met-
Val-Met), a selective FPRL-1 agonist, were purchased from
Tocris (Bristol, UK). The pan-FPR receptor antagonist, BOC-
2 (Boc-Phe-Leu-Phe-Leu-Phe), was purchased from Phoe-
nix Pharmaceuticals (Karlsruhe, Germany). FMLP and,
unless otherwise stated, all other chemicals were pur-
chased from Sigma–Aldrich (Poole, UK).
2.2. Isolation of neutrophils and mononuclear cells
The study was carried out under a Home Ofﬁce licence
with ethical approval from the Royal Veterinary College
Ethics and Welfare Committee and the East London Local
Research Ethics Committee. Blood (up to 200ml from
horses and 60ml fromone human volunteer)was collected
into EDTA (102M), and neutrophils and mononuclear
cells isolated by density gradient centrifugation as pre-
viously described (McKelvie et al., 1998; Rickards et al.,
2001).
2.3. Expression of annexin-1 in equine leucocytes
Equine neutrophils and mononuclear cells (5 106
from 6 and 5 horses, respectively) and human neutrophil
and mononuclear cells (5 106) were lysed (lysis buffer:
7.65mM Tris HCl, 10% (v/v) glycerol and 2% (w/v) SDS
supplemented with protease inhibitors (103M AEBSF (4-
(2-aminoethyl) benzenesulphonyl ﬂuoride hydrochlor-
ide)), 50mg/ml leupeptin and 1mM NaVO3) for 20min
on ice. Following removal of 25ml for protein estimation
using a BCA protein assay kit (Perbio Ltd., Cramlington,
UK), 4 Lammelli’s bufferwas added and samples stored at
80 8C prior to analysis.
Annexin-1 expression was determined by immuno-
blotting. Brieﬂy, samples (2.5mg protein per lane) were
separated by SDS-PAGE using 10% polyacrylamide gels and
a Biorad Mini Protean II system (BioRad, Hemel Hemp-
stead, UK). Proteins were transferred overnight onto a
polyvinylidene ﬂuoride (PVDF) membrane and immuno-
detection of annexin-1 performed using a 1:1500 dilution
of the annexin-1 antibody and a 1:2000 dilution of
secondary antibody. Protein bands were detected using
an enhanced chemiluminescence (ECL) kit (GE Healthcare
UK Limited, Chalfont St Giles, UK).
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equine neutrophils
Equine neutrophils (5 106 in 1 HBSS containing
Ca2+/Mg2+ (Invitrogen, Paisley, UK)) were exposed to
105M Ac2-26 for 2–10min as this concentration was
shown to cause p42/p44 MAPK phosphorylation following
activation of cloned FPR receptors in HEK cells (Hayhoe
et al., 2006) or to PAF (106M) for 2.5min as a positive
control (Cunningham, unpublished data). At the end of the
incubation, samples were placed on ice and lysed for
20min. Following removal of 25ml for protein estimation,
4 Lammelli’s buffer was added and samples stored at
80 8C prior to analysis.
Activation of p42/44 MAPK was examined by immu-
nodetection of the phosphorylated form of the protein
using phospho-p42/44 MAPK and total-p42/44 MAPK
antibodies known to cross react with the equine protein
(Titterton et al., 2004). Protein bands were detected
using an enhanced chemiluminescence (ECL) kit. Films
were then scanned, band densities determined using
Image J image analysis software (http://www.rsb.info.
nih.gov/ij/) and expressed as arbitrary units  SEM (n = 4
horses).
2.5. Superoxide production by equine neutrophils in response
to Ac2-26
Superoxide production was measured colorimetrically
as a reduction in cytochrome (cyt) C (Foster and Cunning-
ham, 1997). Brieﬂy, neutrophils (0.25 106/ml; n = 3
horses) in HBSS/cyt C (2.5mg/ml) were incubated at
37 8C for 5min with cytochalasin (cyt) B (5mg/ml) to
induce priming (Marr et al., 1997; Bylund et al., 2003;
Franck et al., 2009) before addition of agonists or vehicle.
To the authors knowledge there are no reports describing
the effects of Ac2-26 on neutrophil superoxide production
in vitro. Thus the concentrations used (105M and
5 105M) were chosen on the basis of a study on human
neutrophils carried out by Karlsson et al. (2005) in which
another N-terminal annexin 1 peptide, Ac9-25, was shown
to induce a response in the micromolar range. FMLP was
used at the highest concentration tested by Brazil et al.
(1998) in a chemiluminescence assay of free radical
production by equine neutrophils and at a 100-fold higher
concentration (106M and 104M). WKYMVm and
WKYMVM are more potent FPR agonists than FMLP and
were used at 107M as this concentration has been shown
to induce superoxide production by human neutrophils
(Karlsson et al., 2005). Whilst the lack of superoxide
production by FMLP in un-primed equine neutrophils has
been reported (Brazil et al., 1998), the effects of Ac2-26 are
unknown. Therefore responses to the agonists in vehicle
treated cells were examined in parallel. After 30min
neutrophils were removed by centrifugation (875 g,
10min, 4 8C), supernatant (250ml) transferred to a 96-well
plate and read at 550 nm using a Spectra Max Pro plate
reader (Molecular Devices,Wokingham,UK) attached to an
Apple Macintosh running Softmax pro (version 1; Mole-
cular Devices). Results are expressed as mean nmol
reduced cyt C/106 cells SEM.In order to determine whether the effects of Ac2-26
were mediated by FPR binding, BOC-2 (105M; Hayhoe
et al., 2006) or vehicle (0.125% methanol) was added to
neutrophils (n = 3 horses) 10min prior to cyt B. After a
further 5min, Ac2-26 (5 105M), FMLP (106 and
104M), WKYMVm (107M) or vehicle were added and
superoxide productionmeasured 30min later as described
above.
The effect of inhibiting p42/44MAPK activation on FPR-
mediated neutrophil superoxide production (n = 3–5
horses) was determined by pre-incubating neutrophils
with PD98059 (105M; Houliston et al., 2001). After
25min at 37 8C, cyt B was added and 5min later, Ac2-26
(2 105M), FMLP (104M) or WKYMVm (107M).
Superoxide production was measured after a further
30min incubation. An interim study showed that
2 105M Ac2-26 caused signiﬁcant superoxide produc-
tion by equine neutrophils and this concentration was
therefore used in this and subsequent studies for reasons of
cost.
2.6. Effects of Ac2-26 on opsonised zymosan-induced
superoxide release by neutrophils
To examine whether Ac2-26 could reduce the response
to another stimulus, neutrophils (n = 6 horses) were pre-
incubated with the peptide at a concentration that did not
induce superoxide production (105M) or vehicle for
15min prior to addition of serum-treated {opsonised}
zymosan (STZ; 1mg/ml; Foster and Cunningham, 1997).
Superoxide production was measured 30min later. The
effect of adding Ac2-26 at the same time as STZ was also
studied. To determinewhether the inhibitory effect of Ac2-
26 was FPR mediated, neutrophils (n = 3 horses) were pre-
incubated with BOC-2 (105M) or vehicle for 15min prior
to addition of Ac2-26 or vehicle. STZ was added 15min
later and superoxide production measured after a further
30min.
2.7. Statistical analyses
Statistical analyses were carried out using Analyse-It
version 2.12 for Microsoft Excel (Analyse-It software,
Leeds, UK; http://www.analyse-it.com/). One-way analysis
of variance followed by Bonferroni’s test was used to
examine the effects of (i) Ac2-26, FMLP, WKYMVm and
WKYMVM on superoxide production, (ii) BOC-2 and
PD98059 on agonist-induced responses and (iii) Ac2-26
on STZ-induced superoxide production. Throughout, sta-
tistical signiﬁcance was accepted at p< 0.05.
3. Results
3.1. Expression of annexin-1 in equine neutrophils and
mononuclear cells
Equine neutrophils and mononuclear cells expressed a
37 kDa protein that corresponded to the position of a band
in human neutrophils and mononuclear cells recognised
by the anti-annexin-1 antibody (Fig. 1). Although the
peptide was present in all the cell lysates examined, and
Fig. 1. Expression of annexin-1 in (a) equine neutrophils (n = 6 horses) and
(b) mononuclear cells (n = 5 horses) using a polyclonal rabbit anti-human
annexin-1 antibody. Human mononuclear cells and neutrophils (n = 1)
were used as a positive control. Each lane was loadedwith 2.5mg protein.
Fig. 2. Effect of Ac2-26 on p42/44 MAPK phosphorylation in equine
neutrophils. (a) Representative blots showing expression of phospho- and
total-p42/44 MAPK in neutrophils from one horse following stimulation
at 37 8Cwith Ac2-26 (105M) for up to 10min or PAF (106M) for 2.5min
and (b) mean SEM band densities for p42/p44 MAPK expression in
neutrophils from 4 horses. *p< 0.05 versus 0min using one-way ANOVA
followed by Bonferroni’s test.
Fig. 3. Effect of Ac2-26 on superoxide production by equine neutrophils.
Superoxide production by neutrophils pre-incubated for 5min at 37 8C
with cyt B (5mg/ml) prior to addition of Ac2-26, FMLP, WKYMVM or
WKYMVm for 30min. Values are shown as mean nmol reduced cyt C/106
cells SEM (n = 3 horses). *p< 0.05 versus unstimulated cells; one-way
ANOVA followed by Bonferroni’s test.
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each of the 6 horses, there appeared to be some inter-
animal variability in expression by mononuclear cells.
Lymphocytes are reported to contain little annexin-1 in
comparison with neutrophils or monocytes (Morand et al.,
1995). As the equine mononuclear cell lysates contained
both monocytes and lymphocytes, the variation could be
due, at least in part, to a difference in the number of
monocytes present, which was not ascertained.
3.2. Effect of Ac2-26 on p42/44 MAPK phosphorylation in
equine neutrophils
Expression of phospho-p42/44 MAPK in human neu-
trophils signiﬁcantly increased after incubation with PAF
for 2.5min. Ac2-26 (105M) also induced activation of the
kinase in a time dependent manner (Fig. 2). The mean
increase in phospho-p42 MAPK appeared to be more
marked than the increase in phospho-p44MAPK, although
inter-animal variation was evident.
3.3. Effect of Ac2-26 on superoxide production by equine
neutrophils
Ac2-26 at a concentration of 5 105M, but not
105M, induced superoxide production in cyt B-primed
neutrophils, as did FMLP and WKYMVm. In contrast the
FPRL-1 selective agonist, WKYMVM, was without effect
(Fig. 3). At this concentration Ac2-26 also induced super-
oxide production from un-primed cells (11 5 (basal),
*37 10 (5 105 M Ac2-26), 18 8 (105M Ac2-26) nmol
reduced cyt C/106 cells, *p< 0.05; n = 3 horses).
BOC-2 alone had no effect on basal superoxide
production in primed neutrophils but signiﬁcantly inhib-
ited responses to both Ac2-26 and FMLP (Fig. 4a).
Surprisingly, only a small, non-signiﬁcant, reduction in
WKYMVm-induced superoxide production was observed
(Fig. 4a). Superoxide production in response to agonists
was lower in this experiment after pre-treatment with
PD98059 or Ac2-26 (Figs. 4b and 5). This may be because
increasing the length of incubation at 37 8C adversely
affected the ability of the cells to respond to stimuli; basal
superoxide production did not increase.
Superoxide production induced by Ac2-26 (2 105M)
in primed cells was attenuated to basal levels by pre-
treatment with PD98059 (Fig. 4b). The responses to FMLPand WKYMVm were also markedly reduced, although
inhibition was incomplete (Fig. 4b). To determine whether
PD98059 was acting on pathways stimulated by cyt B or
those triggered by FPR/agonist interactions, the effect of
the inhibitor on superoxide production was additionally
Fig. 5. Effect of Ac2-26 on neutrophil superoxide production in response
to serum-treated {opsonised} zymosan. Neutrophils were pre-incubated
for 15min with Ac2-26 before addition of STZ and measurement of
superoxide production 30min later. BOC-2 or vehicle (0.125%MeOH)was
added 15min prior to Ac2-26 and STZ added after a further 15min. Values
are means SEM (n = 6 horses (effect of Ac2-26 on STZ) and n = 3 horses
(effect of BOC-2 on the inhibitory action of Ac2-26)). *p< 0.05 versus STZ
alone; +p< 0.05 versus STZ + Ac2-26. Superoxide production in response to
STZ, STZ following exposure to BOC-2 and STZ following exposure to BOC-2
and Ac2-26 was signiﬁcantly greater than basal; p< 0.05.
Fig. 4. Effect of BOC-2 and PD98059 on agonist-induced superoxide
production. (a) The effect of BOC-2 on agonist-induced superoxide
production. The receptor antagonist was added 10min prior to cyt B
(5mg/ml) followed after 5min by Ac2-26, FMLP orWKYMVm. Superoxide
production was measured after a further 30min. Values are shown as
mean nmol reduced cyt C/106 cells SEM (n = 3 horses). *p< 0.05 versus
the response to agonist alone; one-way ANOVA followed by Bonferroni’s
test. (b) The effect of PD98059 on agonist-induced superoxide production.
TheMEK inhibitor was added 25min prior to cyt B (5mg/ml) followed 5min
later by Ac2-26, FMLP or WKYMVm. Values are shown as mean nmol
reduced cyt C/106 cells SEM (n = 3 horses for FMLP andWKYMVmand n = 5
horses for Ac2-26). *p< 0.05 versus the response to agonist alone; one-way
ANOVA followed by Bonferroni’s test.
Table 1
Effect of PD98059 (105M) on (a) Ac2-26-induced superoxide production
by un-primed equine neutrophils and (b) inhibition of STZ-induced
superoxide production by Ac2-26.
Treatment Superoxide
(nmol reduced
cyt C/106 cells)
(a) Vehicle 8 0.2
Ac2-26 (2 105M) 18 1
Ac2-26 (2 105M) + PD98059 (105M) 6 2*
(b) STZ alone 42 4
PD98059 (105M) alone 9 0.2
PD98059 (105M) + STZ 38 6
Ac2-26 (105M) + STZ 19 1*
PD98059 (105M) + Ac2-26 (105M) + STZ 32 3+
Values are means SEM nmol reduced cyt C/106 cells (n = 4 horses).
* p< 0.05 versus stimulus alone; one-way ANOVA followed by
Bonferroni’s test.
+ p< 0.05 versus STZ in Ac2-26 pre-treated cells; one-way ANOVA
followed by Bonferroni’s test.
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(2 105M). PD98059 was found to completely inhibit
superoxide production in un-primed cells following
exposure to Ac2-26 (Table 1).
3.4. Effect of Ac2-26 on zymosan-induced superoxide
production by equine neutrophils
Pre-incubation with Ac2-26, at a concentration that
caused no superoxide production in un-primed cells,
signiﬁcantly reduced the response to STZ (Fig. 5) but the
peptide had no effect when added at the same time as the
stimulus (49 9 (STZ/Ac2-26) versus 51 11 (STZ) nmol
reduced cyt C/106 cells). The inhibitory effect of Ac2-26 was
signiﬁcantly attenuatedbypre-treatment of the cells byBOC-2
(Fig. 5).Whilst pre-treatmentwithPD98059hadno signiﬁcant
effect on STZ-induced superoxide production, it did attenuate
the reduction in response caused by Ac2-26 (Table 1).
4. Discussion
Regulation of neutrophil function is essential in order to
prevent inappropriate activation during the host defenceresponse and, in the otherwise healthy individual, this is
achieved by a balance between the actions of endogen-
ously produced pro- and anti-inﬂammatory mediators
(Perretti et al., 2001; Yang et al., 2004; Gavins et al., 2006).
The inhibitory effects of the anti-inﬂammatory peptide,
annexin-1, on human neutrophil function are well
documented (reviewed in Perretti and Flower, 2004;
Perretti and D’Acquisto, 2009). Although equine
annexin-1 has been sequenced (Bryant et al., 2002), the
present study is the ﬁrst to demonstrate that the peptide is
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in leucocytes from other species has been established
(Comera and Russo-Marie, 1995; Oliani et al., 2002;
Perretti and D’Acquisto, 2009). Moreover, it has been
shown that, in unstimulated neutrophils, annexin-1 is co-
localised with gelatinase-rich tertiary granules (Perretti
et al., 2000) and is rapidly mobilised to the surface on
activation, such as occurs when cells adhere to the
endothelium (Perretti and Gavins, 2003; Perretti and
D’Acquisto, 2009). As in other species, annexin 1 was
found to be present in horse neutrophils and mononuclear
cells. Lymphocytes have been reported to contain little
annexin-1 in comparison with monocytes (Morand et al.,
1995) but further studies are required to establish the
relative expression in these equine cell populations, aswell
as the intracellular localisation in both stimulated and
unstimulated equine leucocytes.
Following externalisation, annexin 1 acts in an auto-
crine fashion by binding to FPR receptors, reducing
neutrophil extravasation (Perretti and Gavins, 2003;
Perretti and D’Acquisto, 2009). However, if N-terminal
cleavage occurs, peptides such as Ac2-26 and Ac9-25 are
formed (Movitz and Dahlgren, 2000) and, in vitro, Ac9-25
has been shown to both inhibit free radical production by
human neutrophils in response to other stimuli and to
induce the formation of free radicals (Karlsson et al., 2005).
The present study has shown that the effects of Ac2-26 on
equine neutrophil superoxide production appear to be
similar to those of Ac9-25 on human neutrophils.
That Ac2-26-induced superoxide production by both
cyt B-primed and un-primed cells was almost completely
inhibited by BOC-2 suggests that the stimulatory effect of
the annexin-1 peptide was mediated by activation of an
FPR. Although BOC-2 is described as a pan-FPR antagonist
and should therefore reduce agonist binding to both FPR
and FPRL-1 on neutrophils, Stenfeldt et al. (2007)
suggested that BOC peptides and cyclosporin H are ‘‘fairly
speciﬁc’’ FPR antagonists. This, together with the observa-
tion that the selective FPRL-1 agonist, WKYMVM, caused
no superoxide production by equine neutrophils, and the
presence of a single receptor population on these cells that
binds FMLPwith a similar afﬁnity to human neutrophil FPR
(Brazil et al., 1998), suggests that the effects of Ac2-26 are
indeed FPR mediated. FMLP and WKYMVm activate both
FPR and FPRL-1 and FMLP-induced superoxide production
by equine neutrophils was blocked by BOC-2. Why BOC-2
was able to reduce responses to Ac2-26 and FMLP, but
caused little attenuation of superoxide production by
WKYMVm, is therefore difﬁcult to explain. It is possible
that, asWKYMVm is more potent than either FMLP or Ac2-
26, the concentration of BOC-2 used was too low to be
effective. This seems unlikely, however, as the antagonist
was present at a 100-fold higher concentration than
WKYMVm, although the IC50 has not been established in
the horse. At concentrations above 105M, BOC-2 is
reported to lose selectivity of action on neutrophil formyl
peptide receptors (Stenfeldt et al., 2007). Therefore higher
concentrations were not tested in this study as any
functional inhibition observed might not be due to an
FPR-mediated effect. As in equine neutrophils, inhibition of
FPR had no effect on WKYMVm-induced superoxideproduction by human neutrophils (Karlsson et al., 2006).
A selective inhibitor of FPRL-1 was also without effect
when 107MWKYMVmwas used, as in the present study,
and was only partially effective at reducing the effects of
lower concentrations of the peptide (Karlsson et al., 2006).
Although these ﬁndings suggested that WKYMVm might
be acting on a different type of cell surface receptor, this
possibilitywas excluded as combined inhibition of FPR and
FPRL-1 did block the response. The explanation for their
ﬁndings put forward by the authors related to hierarchical
cross-talk between FPR and FPRL-1, both of which are
present on human neutrophils. However, this could not
explain the lack of effect of BOC-2 on WKYMVm-induced
superoxide production by equine cells which express only
a single receptor population and the underlying mechan-
ism therefore remains to be determined.
It was also of interest that Ac2-26 promoted the
production of a small, but signiﬁcant, amount of super-
oxide by un-primed neutrophils whereas FMLP and
WKYMVm were without effect. Whether this can be
explained by differential activation of one or more
intracellular signalling molecules by the agonists may
become clear once the pathways activated downstream of
the cell surface receptor have been delineated.
Ac2-26 was shown to activate p42/44 MAPK in equine
neutrophils, which is in agreement with previously
published work in HEK cells transfected with human
FPR and FPRL-1 (Hayhoe et al., 2006). Moreover, as
superoxide production by both un-primed and primed
equine cells in response to Ac2-26 was abolished in the
presence of PD98059, it suggests that activation of p42/44
MAPK is required for this response. Activation of p42/44
MAPK is also a necessary step for superoxide production in
response to FMLP or WKYMVm in human neutrophils and
eosinophils, respectively (Dewas et al., 2000; Shin et al.,
2005), and the ﬁndings in primed equine neutrophils are
consistent with this. Further studies are required to
determine whether p42/44 MAPK activation by FPR
agonists inﬂuences the phosphorylation of NADPH oxidase
subunits, as has been shown in human neutrophils
stimulated with FMLP (Dewas et al., 2000). Activation of
p38 MAPK is also involved in the production of reactive
oxygen species by neutrophils stimulated with FMLP
(Dang et al., 2006; Sakamoto et al., 2006). However, as p38
MAPK activation was not shown to occur following Ac2-26
binding to FPR or FPRL-1 in HEK cells (Hayhoe et al., 2006),
activation of this kinase in equine neutrophils and its role,
if any, in superoxide production caused by Ac2-26 was not
investigated as a part of this study.
The oxidative burst which occurs following stimulation
of equine neutrophils with serum-treated {opsonised}
zymosan was signiﬁcantly attenuated following pre-
incubation with Ac2-26 at a concentration which alone
caused no signiﬁcant superoxide production. Addition of
Ac2-26 at the same time as STZ had no signiﬁcant effect,
suggesting that the peptide may be affecting downstream
signalling events involved in mediating the response to
this particulate stimulus. That the inhibition required Ac2-
26 binding to FPR and activation of p42/44 MAPK is
indicated by the ability of BOC-2 and PD98059 to decrease
the inhibitory effect. Studies in rodents have suggested
K.J. Pickles et al. / Veterinary Immunology and Immunopathology 135 (2010) 226–233232that the inhibitory effects of Ac2-26 on neutrophil function
are mediated by the peptide binding to the murine
analogue of FPRL-1 (Gastardelo et al., 2009). Hayhoe
et al. (2006), however, found that an FPRL-1 antibody did
not affect the inhibitory action of Ac2-26 on human
neutrophil rolling in vitro although the effect was blocked
by BOC-2. In contrast, Karlsson et al. (2005) have suggested
that the inhibition of human neutrophil superoxide
production obtained with Ac9-25 is mediated by an, as
yet unidentiﬁed, receptor. As the inhibitory effects of Ac2-
26 in murine, human and equine cells all appear to be
mediated by members of the family of FPR receptors it
suggests that Ac9-25 may behave differently to Ac2-26.
The observation that pre-treatment of equine neutro-
phils with PD98059 inhibits superoxide production in
response to Ac2-26 (5 105M) and reverses the inhibi-
tory effect of 105M Ac2-26 on the response to STZ
appears somewhat contradictory as it implies that activa-
tion of p42/44MAPK is required to both induce and inhibit
the same response. However, PD98059 does not directly
inhibit activation of p42/44 MAPK but rather that of the
upstream kinase, MEK. Although PD98059 is a selective
MEK inhibitor it can inhibit the activation of related
kinases such as MEK5, and hence activation of ERK5 (Bain
et al., 2007). Thus it is possible that it is the consequence of
inhibition of different, or additional, signalling molecules
downstream of MEK activation that is responsible for
either the stimulatory or inhibitory effects of Ac2-26 on
superoxide production by equine neutrophils.
In summary, neutrophils play a key role in host defence
against invading pathogens but do also contribute to the
pathogenesis of common equine inﬂammatory diseases
such as laminitis (Black et al., 2006; Hurley et al., 2006),
recurrent airway obstruction (Fairbairn et al., 1993) and
endotoxaemia (Hedges et al., 2001). The actions of
endogenous anti-inﬂammatory mediators are one means
by which inappropriate neutrophil activation can be
prevented. The present study supports the hypothesis
that annexin-1 may help to down-regulate equine
neutrophil superoxide production. There are as yet no
reports demonstrating that generation of Ac2-26 occurs in
inﬂamed tissue but Hayhoe et al. (2006) have speculated
that it is unlikely high micromolar concentrations of N-
terminal annexin 1 peptides will be attained in vivo. Thus,
although this in vitro study has shown that Ac2-26 has the
potential to promote tissue damage in equine disease by
increasing localised free radical production, the negative
regulatory role of annexin 1 peptides may be of greater
importance in vivo. Indeed, by reducing neutrophil
accumulation in vivo, intravenous administration of Ac2-
26 has been shown to be protective in a rat model of
myocardial ischaemia reperfusion injury during which
activated cells can contribute to tissue damage by the
release of free radicals (La et al., 2001).
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